T1	Participants 541 655	five cohorts comprising 40 individuals with a single administration of A4250 (0.1, 0.3, 1, 3, or 10 mg) or placebo
T2	Participants 660 793	three cohorts comprising 24 individuals with a 1-week administration of A4250 (1 or 3 mg once daily or 1.5 mg twice daily) or placebo
T3	Participants 1774 1814	patients with cholestatic liver diseases
